INTRODUCTION: IL-40 is a novel cytokine associated with autoimmune connective tissue disorders such as rheumatoid arthritis (RA) or Sjögren syndrome. We have previously shown an accumulation of IL-40 in the RA joint and its expression by immune cells and fibroblasts. Therefore, we aimed to assess the role of IL-40 in association with hyaline cartilage and chondrocyte activity. METHODS: Immunohistochemistry was employed to detect IL-40 in paired samples of loaded and unloaded regions of osteoarthritis (OA) cartilage (n=5). Synovial fluid IL-40 was analysed by ELISA in OA (n=31) and control individuals after knee injury (n=34). The impact of IL-40 on chondrocytes was tested in vitro. RESULTS: IL-40 was found in chondrocytes of the superficial zone of the OA cartilage, both in loaded and unloaded explants. Additionally, only biopsies from loaded explants showed significant IL-40 positivity in transitional zone chondrocytes. Levels of IL-40 were significantly elevated in the synovial fluid from OA patients compared to controls (p<0.0009) and correlated with synovial fluid leukocyte counts in OA (r=0.444, p=0.014). Chondrocytes exposed to IL-40 dose dependently increased in the secretion of pro-inflammatory cytokines IL-6 (p<0.0001) and IL-8 (p=0.004). Moreover, a dose dependent up-regulation of matrix degrading metalloproteinases MMP-1 (p=0.004), MMP-3 (p=0.031) and MMP-13 (p=0.0002) upon IL-40 treatment was observed in contrast to untreated chondrocytes. CONCLUSION: This study is the first to demonstrate the accumulation of IL-40 in OA cartilage and its up-regulation in the synovial fluid of OA patients compared to controls. In addition, extracellular IL-40 appears to play a role in promoting inflammation and cartilage destruction by driving chondrocyte behaviour towards a more aggressive phenotype.
- MeSH
- chondrocyty * metabolismus patologie MeSH
- dospělí MeSH
- ELISA MeSH
- fenotyp MeSH
- imunohistochemie MeSH
- interleukiny * metabolismus MeSH
- kloubní chrupavka metabolismus patologie MeSH
- kultivované buňky MeSH
- lidé středního věku MeSH
- lidé MeSH
- osteoartróza * metabolismus patologie MeSH
- senioři MeSH
- synoviální tekutina * metabolismus MeSH
- upregulace MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Fibroblast growth factor-21 (FGF-21) has been recently characterized as a new adipokine. The aim of this study was to assess FGF-21 levels in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) and to study the relationship between FGF-21, disease activity and metabolic status. The levels of FGF-21 in serum and synovial fluid samples from 38 patients with RA and 42 control individuals with OA were determined by ELISA. Patients were assessed for disease activity using the disease activity score (DAS28), a serum glucose and lipid profile. Age, sex and BMI-adjusted FGF-21 levels in the serum (p=0.024) and synovial fluid (p=0.010) samples were significantly higher in patients with RA when compared with OA. The levels of FGF-21 in the serum significantly correlated with the levels in the synovial fluid. Serum and synovial fluid FGF-21 levels adjusted for confounders correlated positively with C-reactive protein. The levels of FGF-21 were positively correlated with BMI in patients with RA; however, the levels were not associated with disease activity or lipid profiles. Furthermore, serum FGF-21 levels were significantly higher in seropositive compared with seronegative RA patients. This work shows that patients with seropositive RA have increased levels of FGF-21. The results suggest that FGF-21 is related to BMI but not disease activity or lipid profiles in patients with RA.
- MeSH
- adipokiny krev MeSH
- biologické markery krev MeSH
- fibroblastové růstové faktory krev MeSH
- index tělesné hmotnosti * MeSH
- lidé středního věku MeSH
- lidé MeSH
- reprodukovatelnost výsledků MeSH
- revmatoidní artritida metabolismus MeSH
- senioři MeSH
- senzitivita a specificita MeSH
- synoviální tekutina metabolismus MeSH
- upregulace MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
To investigate the effect of intensive physiotherapy on disease activity and serum levels of adipocytokines in patients with ankylosing spondylitis (AS). Twenty-six patients with AS were included in this study. Intensive physiotherapy was performed twice a week for a period of 3 months. The Bath AS Disease Activity Index (BASDAI) and the Bath AS Functional Index (BASFI) were assessed at inclusion and after 3 months. Leptin, adiponectin, resistin and visfatin serum levels were analysed by ELISA assays. Patients had mild to moderate disease activity. Baseline levels of adipocytokines did not correlate with indicators of disease activity, functional status or acute-phase reactants. After the 3 months of intensive physiotherapy, BASDAI significantly decreased from 2.98 to 1.8 (p = 0.01) and BASFI improved from 2.31 to 1.37 (p = 0.05), while there were no changes in serum levels of CRP, ESR and adipocytokines. In addition, baseline levels of adipocytokines did not predict the change of disease activity or functional ability. Intensive physiotherapy effectively reduces all clinical measures of disease activity, but it is not associated with a significant change in acute-phase reactants or serum levels of adipocytokines.
- MeSH
- adipokiny krev MeSH
- ankylózující spondylitida krev patofyziologie terapie MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- stupeň závažnosti nemoci MeSH
- terapie cvičením metody MeSH
- výsledek terapie MeSH
- zdravotní stav MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
V poslednom desaťročí sa v klinickej praxi začali uplatňovať nové protinádorové preparáty označované pre svoj špecifický účinok termínom „cielená“ liečba. Prostriedkami cielenej terapie sú monoklonálne protilátky, inhibítory tyrozínkináz, inhibítory proteazómov a angiogenézy. Napriek ich nespornému medicínskemu prínosu sa s využitím tejto terapie spája množstvo nežiadúcich účinkov, pričom medzi najčastejšie radíme nežiaduce účinky na kožu. Tieto prejavy sú veľmi často pozorované pri terapii látkami inhibujúcimi aktivitu epidermálneho rastového faktora a jeho receptora.
In the last decade a new agents of anticancer therapy have been introduced. These agents include monoclonal antibodies, tyrosine kinase inhibitors, proteasome inhibitors and inhibitors of angiogenesis. Even though the targeted therapy is very effective it is associated with a lot of different side-effects, of which cutaneous are the most common. These are very often observed during therapy with inhibitors of epidermal growth factor and of its receptor.
- MeSH
- akneiformní erupce chemicky indukované klasifikace MeSH
- alopecie chemicky indukované MeSH
- antitumorózní látky škodlivé účinky terapeutické užití MeSH
- erbB receptory antagonisté a inhibitory MeSH
- kožní nemoci chemicky indukované MeSH
- lidé MeSH
- monoklonální protilátky škodlivé účinky MeSH
- paronychie chemicky indukované MeSH
- pruritus chemicky indukované MeSH
- Check Tag
- lidé MeSH
Metastatické kožné karcinómy vznikajú metastazovaním karcinómov vnútorných orgánov per continuitatem, hematogénnou alebo lymfogénnou cestou. Ich výskyt je vzácny, približne u 3 až 5 percentách pacientov s metastazujúcimi tumormi dochádza ku vzniku kožných metastáz, ktoré môžu byť prvou známkou metastazujúceho karcinómu iného orgánu. Uvádzame prípad 66-ročného muža bez anamnézy onkologického ochorenia, vyšetreného pre nález rastúcich kožných exofytických uzlov lokalizovaných na tvári a hrudi, histologicky verifikovaných ako kožné metastázy svetlobunkového karcinómu z buniek obličky.
Metastatic skin carcinomas originate from visceral carcinomas metastasizing per continuitatem, via blood or lymphatic vessels. The skin metastases develop rarely, approximately in 3–5 % of patients with metastatic tumors, and might represent the first sign of other organ carcinoma metastases. We present a case of a 66-year-old male without history of oncological disease, examined because of growing cutaneous exophytic nodules localized on the face and chest that were histologically verified as cutaneous metastases of a clear cell renal carcinoma.
- MeSH
- karcinom z renálních buněk diagnóza MeSH
- lidé MeSH
- metastázy nádorů diagnóza MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- kazuistiky MeSH
